Biotech & Health Tech
Rasonque sales drives RevMed's stock; whistleblower sues Madrigal over MASH
Plus news about Rezera, ANI Pharmaceuticals, Cloudbreak Pharma and Anaheim Bio. RevMed’s stock jumps on early Rasonque sales: The RAS drug developer reported sales of its pancreatic cancer therapy Rasonque for the first time, netting ...
Plus news about Rezera, ANI Pharmaceuticals, Cloudbreak Pharma and Anaheim Bio. RevMed’s stock jumps on early Rasonque sales: The RAS drug developer reported sales of its pancreatic cancer therapy Rasonque for the first time, netting ...
This is a summary of the story. Read the full article at Endpoints News (Biopharma) ↗